Verona Pharma 2022 Respiratory Disease Therapies Investor Presentation

Verona Pharma presents its Phase 3 candidate ensifentrine, a first-in-class dual PDE3/PDE4 inhibitor for COPD maintenance treatment. The presentation outlines a $10.5B US market opportunity with over 1M symptomatic patients despite dual/triple therapy, highlighting the drug's novel mechanism, demonstrated efficacy in Phase 2b trials, and favorable safety profile.